



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#15
Dmt
5-16-03
IVED

Applicant(s): Bendele et al.

Serial No.: 09/907,263

Group Art Unit No.: 1646

MAY 14 2003

Filed: July 17, 2001

Examiner: E. O'Hara

TECH CENTER 1600/2900

For: COMBINATION THERAPY USING A TNF
BINDING PROTEIN FOR TREATING TNF-
MEDIATED DISEASES

Docket No.: A-430F

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As requested by Examiner O'Hara in her Office Action dated December 31, 2002, Applicants herewith submit another copy of the references as set forth in the attached PTO-1449, which were filed August 30, 2002 (Paper No. 9).

Applicants' position regarding this information and its relevancy remains unchanged.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Timothy J. Gaul
Attorney for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date: May 7, 2003

Please send all future correspondence to:
US Patent Operations/ TJG
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EV 351340134 US

Date of Deposit: May 7, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum
Printed Name

Lynne Buchsbaum
Signature